News

Moment and Crown Holdings Innovate with Sustainable Packaging

Moment and Crown Holdings Innovate with Sustainable Packaging

Transforming Beverage Packaging with Sustainability

Introduction to Moment's Innovative Approach

Moment, a pioneering botanical soda brand, is making significant strides in sustainable beverage packaging. Partnering with Crown Holdings, Inc. (NYSE: CCK), Moment is enhancing its product offerings by upgrading packaging materials to promote environmental responsibility. This collaboration aims to meet the rising consumer demand for healthier, eco-friendly options in the beverage market.

Upgrading Packaging for a Greener Future

Moment will shift from traditional shrink-wrapped aluminum cans to directly printed cans with improved sustainability features. This transformation is expected to bolster package circularity and reduce Moment's overall environmental impact. The decision to collaborate with Crown for this initiative stems from their extensive expertise in packaging design, sustainability practices, and technical support, which are vital for achieving higher standards in eco-friendly packaging.

Consumer Preferences Drive Change

Bryan Sahadi, Senior Manager of Marketing and Commercial Operations at Crown, expressed optimism about the partnership, highlighting its alignment with consumer preferences for modern soda options. With health-conscious customers seeking not only low-calorie beverages but also those that uphold environmental values, Moment is poised to appeal to this growing demographic. The transition to more sustainable packaging reflects a larger trend in the beverage industry aimed at reducing environmental footprints.

Broadening the Reach of Moment's Offerings

Moment's collaboration with Crown will enable the brand to launch six popular SKUs in eco-friendly packaging, ensuring that the transition enhances the consumer experience. Aisha Chottani, Moment's founder and CEO, remarked on the motivation behind selecting Crown, noting their capability in supply chain sustainability and impressive shelf appeal. This partnership is a strategic move to broaden Moment's presence while maintaining the unique essence of its brand.

Highlighting Unique Flavors

The revamped product range will feature enticing flavors such as Sparkling Blackberry Lavender and Still Blueberry Ginger, formulated with South Asian-inspired ingredients like ashwagandha and L-theanine that support mental clarity and stress relief. Each can reflects the tagline "Drink Your Meditation," appealing to wellness-focused individuals. This exciting concoction not only satisfies the thirst for flavorful beverages but also caters to the rising trends among consumers who prefer non-alcoholic and low-calorie options, especially during festive seasons.

Growth through Innovative Marketing Strategies

Moment's journey has been marked by incredible growth, especially after appearing on the popular reality show. With a reported 400% increase in sales, the brand has significantly expanded, with plans for further advancements. The new aluminum cans are designed to enhance product transparency while maintaining a vibrant and eye-catching design, ensuring that consumers are drawn to them both visually and ethically.

Future Availability and Distribution

By early 2025, consumers can expect to find all of Moment's newly transitioned SKUs in 12-oz CrownSleek cans across key regions, beginning with a rollout in the Midwest and Northeast, followed by launches on the West Coast. The commitment to sustainability will not only boost the brand's visibility but also encourage environmental awareness among consumers.

About Moment and Its Mission

Moment is a female- and minority-owned beverage company that focuses on creating natural botanical-based drinks aimed at boosting mental clarity and alleviating stress. With a low-calorie, non-GMO formulation, Moment strives to offer flavorful beverages that contribute positively to well-being. Furthermore, as part of their commitment to social responsibility, the brand allocates 1% of profits to mental health non-profits.

Capsules and Closures, LLC Contribution

Supporting Moment's packaging transition, Capsules and Closures, LLC offers specialized closure solutions, helping to ensure product integrity during transport and storage. Their expertise in providing high-quality can solutions underscores the importance of partnerships in achieving broader sustainability goals within the beverage industry.

Frequently Asked Questions

What is the main goal of Moment's partnership with Crown Holdings?

The partnership aims to enhance sustainability by transitioning to eco-friendly packaging while maintaining high product quality.

What are some flavors of Moment's beverages?

Moment offers flavors like Sparkling Blackberry Lavender and Still Blueberry Ginger, infused with ingredients known for their mental clarity benefits.

When will the new packaging be available to consumers?

Moment's new products will be available in early 2025, starting with select regions across the Midwest and Northeast.

What makes Moment unique in the beverage market?

Moment is a female- and minority-owned brand focused on natural formulations that promote wellness without added sugar, catering to health-conscious consumers.

How does Moment contribute to social causes?

Moment shares 1% of its profits with mental health non-profits, emphasizing its commitment to both sustainability and social responsibility.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading